Ceftobiprole Medocaril Sodium — Active Pharmaceutical Ingredient

Ceftobiprole Medocaril Sodium is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: POWDER. Routes: INTRAVENOUS.

Drug Ingredients A–Z 1 min read
This content is for informational purposes only. Always consult a healthcare professional.

Ceftobiprole Medocaril Sodium (1 brand name, 1 dosage form, 1 route)

Available dosage forms: POWDER.

Routes of administration: INTRAVENOUS.

Brand Names

  • ZEVTERA

Contraindications

ZEVTERA is contraindicated in patients with a known history of severe hypersensitivity to ZEVTERA, or to other members of the cephalosporin class [see Warnings and Precautions (5.2)].

Adverse Reactions

The following adverse reactions are discussed in greater detail in the Warnings and Precautions section: Increased Mortality in Ventilator-Associated Bacterial Pneumonia Patients [see Warnings and Precautions (5.1)] Hypersensitivity Reactions [see Contraindications (4) and Warning and Precautions (5.2)] Seizures and Other Central Nervous System Reactions [see Warnings and Precautions (5.3)] Clostridioides difficile-Associated Diarrhea [see Warnings and Precautions (5.4)]

Mechanism of Action

ZEVTERA is an antibacterial drug [see Microbiology (12.4)]

Overdosage

There is no information on clinical signs and symptoms associated with an overdose of ZEVTERA. For patients who receive doses greater than the recommended dosage regimen and have unexpected adverse reactions associated with ZEVTERA, discontinue ZEVTERA, treat symptomatically, and institute general supportive treatment. ZEVTERA can be removed by hemodialysis. However, no information is available on the use of hemodialysis to treat overdose [see Clinical Pharmacology (12.3)].

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.